BusinessSelecta Biosciences Reports Data from Ongoing Phase 2 Trial of Lead Candidate, SEL-212, in Development for Chronic Severe GoutBy Nasdaq OMXJun 15, 2017, 11:30 AM UTC
BusinessLonza and Selecta Biosciences Announce Manufacturing Agreement for Anc80-AAV-Based Gene Therapy for Treatment of Methylmalonic AcidemiaBy Nasdaq OMXFeb 16, 2017, 12:01 PM UTC
BusinessLonza and Selecta Biosciences Announce Manufacturing Agreement for Anc80-AAV-Based Gene Therapy for Treatment of Methylmalonic AcidemiaBy Nasdaq OMXFeb 16, 2017, 12:01 PM UTC
BusinessSelecta Biosciences Announces Preclinical Data Showing SVP-Rapamycin’s Potential Benefit in Treatment of Pompe DiseaseBy Nasdaq OMXFeb 15, 2017, 1:00 PM UTC
BusinessSelecta Biosciences Presents Preclinical Data Regarding SVP-Enabled Peanut Allergy Therapeutic Vaccine and Celiac Disease TreatmentBy Nasdaq OMXFeb 6, 2017, 1:00 PM UTC
BusinessSelecta Biosciences to Participate in Two Investor Conferences in FebruaryBy Nasdaq OMXJan 31, 2017, 1:00 PM UTC
